Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2020 05/26/2020 05/27/2020 05/28/2020 05/29/2020 Date
569.91(c) 545.21(c) 544.01(c) 578.21(c) 612.81 Last
653 533 3 742 044 5 902 647 7 869 786 6 675 221 Volume
+1.60% -4.33% -0.22% +6.29% +5.98% Change
More quotes
Financials (USD)
Sales 2020 7 556 M - -
Net income 2020 2 649 M - -
Net cash position 2020 5 882 M - -
P/E ratio 2020 25,4x
Yield 2020 -
Sales 2021 8 820 M - -
Net income 2021 3 112 M - -
Net cash position 2021 9 080 M - -
P/E ratio 2021 22,1x
Yield 2021 -
Capitalization 64 390 M 64 390 M -
EV / Sales 2020 7,74x
EV / Sales 2021 6,27x
Nbr of Employees 8 030
Free-Float 71,3%
More Financials
Company
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows: - sales of products (61.5%); - supply of collaborative services (33.3%): working with Sanofi (54.5% of sales) and Bayer (45.5%); - sales of technology licenses (5.2%). The group also provides subcontracting... 
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
04:10pREGENERON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Re..
AQ
04:02pREGENERON PHARMACEUTICALS : Completes Secondary Offering of Common Stock Held by..
PR
10:39aTAKE FIVE : Hong Kong takes centre stage
RE
05/28SANOFI : to Offload Stake in Regeneron
DJ
05/27NEWS HIGHLIGHTS : Top Company News of the Day
DJ
05/27REGENERON PHARMACEUTICALS : FDA Approves Dupixent as First Biologic Medicine for..
AQ
05/27SANOFI : to Sell Regeneron Shares Worth $11.1 Billion to Fund Overhaul
DJ
05/27Rising Swiss rivalry as Roche and Novartis target same diseases
RE
05/27Drugmaker Sanofi to raise over $11 billion via sale of Regeneron shares
RE
05/27SANOFI : to Raise Up to $11.7 Billion in Regeneron Stake Sale
DJ
05/26REGENERON PHARMACEUTICALS : Announces Pricing of Secondary Offering of its Commo..
PR
05/26Novavax, Merck rise; Regeneron, Anaplan fall
AQ
05/26REGENERON PHARMACEUTICALS : FDA Approves Dupixent for Some Children With Atopic ..
DJ
05/26REGENERON PHARMACEUTICALS : FDA Approves Dupixent® (dupilumab) as First Biologic..
PR
05/26EUROPE : Travel firms propel European stocks to strongest close in 11 weeks
RE
More news
News in other languages on REGENERON PHARMACEUTICALS
04:10pREGENERON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Re..
04:05pSANOFI : clôture la vente de ses titres Regeneron pour $11,7 mds
04:02pREGENERON PHARMACEUTICALS : Completes Secondary Offering of Common Stock Held by..
10:39aTAKE FIVE : Hong Kong takes centre stage
05/28SANOFI : to Offload Stake in Regeneron
More news
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 581,70 $
Last Close Price 612,81 $
Spread / Highest target 19,8%
Spread / Average Target -5,08%
Spread / Lowest Target -34,7%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Executive VP-Finance
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS53.99%64 390
GILEAD SCIENCES15.91%94 479
VERTEX PHARMACEUTICALS26.69%71 918
WUXI APPTEC CO., LTD.15.61%32 212
GENMAB A/S39.93%20 070
BEIGENE, LTD.-2.05%12 591